Effect of Adjuvant Chemotherapy on Stage II Colon Cancer: Analysis of Korean National Data
Authors:
Open Access
- 15 October 2018
- journal article
- research article
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 50 (4) , 1149-1163
Abstract
Purpose Debates exist regarding the effectiveness of adjuvant chemotherapy for stage II colon cancer. This study aimed to investigate the current status of adjuvant chemotherapy and its impact on survival for Korean stage II colon cancer patients by analyzing the National Quality Assessment data. Materials and Methods A total of 7,880 patients who underwent curative resection for stage II colon adenocarcinoma between January 2011 and December 2014 in Korea were selected randomly as evaluation subjects for the quality assessment. The factors that influenced overall survival were identified. The high-risk group was defined as having at least one of the following: perforation/obstruction, lymph node harvest less than 12, lymphovascular/perineural invasion, positive resection margin, poor differentiation, or pathologic T4 stage. Results The median follow-up period was 38 months (range, 1 to 63 months). Chemotherapy was a favorable prognostic factor for either the high-(hazard ratio [HR], 0.76; 95% confidence interval [CI], 0.38 to 0.59; p < 0.001) or low-risk group (HR, 0.74; 95% CI, 0.61 to 0.89; p=0.002) in multivariate analysis. This was also the case in patients over 70 years of age. The hazard ratio was significantly increased as the number of involved risk factors was increased in patients who didn't receive chemotherapy. Adding oxaliplatin showed no difference in survival (HR, 1.36; 95% CI, 0.91 to 2.03; p=0.132). Conclusion Adjuvant chemotherapy can be recommended for stage II colon cancer patients, but the addition of oxaliplatin to the regimen must be selective.Keywords
This publication has 27 references indexed in Scilit:
- The effect of age and comorbidity on patient-centered health outcomes in patients receiving adjuvant chemotherapy for colon cancerJournal of Geriatric Oncology, 2013
- High‐risk stage II colon cancer after curative resectionJournal of Surgical Oncology, 2011
- Effectiveness of Adjuvant Chemotherapy with 5-FU/Leucovorin and Prognosis in Stage II Colon CancerJournal of the Korean Society of Coloproctology, 2011
- Surviving Chemotherapy for Colon Cancer and Living with the ConsequencesJournal of Palliative Medicine, 2010
- Long-Term Survival Results of Surgery Alone Versus Surgery Plus 5-Fluorouracil and Leucovorin for Stage II and Stage III Colon Cancer: Pooled Analysis of NSABP C-01 Through C-05. A Baseline from Which to Compare Modern Adjuvant TrialsAnnals of Surgical Oncology, 2010
- Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07Journal of Clinical Oncology, 2007
- Social deprivation and outcomes in colorectal cancerBritish Journal of Surgery, 2006
- Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?Journal of Clinical Oncology, 2004
- Should Dukes' B patients receive adjuvant therapy? A statistical perspectiveSeminars in Oncology, 2001
- Should Dukes' B patients receive adjuvant therapy? A statistical perspectiveSeminars in Oncology, 2001